KRAS and hepatocellular carcinoma: Instead, on comparison, erlotinib had a dismal effect on the growth of the BRAF class 1–mutated cell line (HCC-364: IC50, 5.81 μM; SE, 0.12) and the KRAS-mutated cell line (ADK-17: IC50, >10; Fig 3D).